January 1, 2016Circulation Journal3 citationsOpen Access

Atrial Fibrillation and Heart Failure – Identification of Patients at Risk –

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Congestive Heart Failure (n=2219). Intervention: Ischemic heart disease, left atrial diameter >4.5 cm, and age >50 years vs. Absence of these combined risk factors. Primary outcome: New-onset atrial fibrillation (2.5-fold greater risk).

DKDavid E. Krummen

Key Result

In patients with congestive heart failure, the combination of ischemic heart disease, left atrial diameter >4.5 cm, and age >50 years was associated with a 2.5-fold greater risk of developing new-onset atrial fibrillation.

PICO

Population

2,219 patients with congestive heart failure from the WARCEF trial followed for a mean of 3.5 years to assess the incidence of new-onset atrial fibrillation.

Exposure / Comparator

Ischemic heart disease, left atrial diameter >4.5 cm, and age >50 years vs Absence of these combined risk factors

Primary Outcome

New-onset atrial fibrillation — 2.5-fold greater risk

Main Result

Relative Risk: 2.5

Limitations

The study was a secondary analysis of the WARCEF trial, so results must be interpreted with caution.
Just over half of the study patients had echocardiographic data available, and differences between the echo and non-echo groups may introduce potential bias.

Abstract

useful for designing strategies to monitor detect AF before or events occur.

问 AI

Bookmark

View Full Paper